# SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation

> **NCT05480865** · PHASE1 · TERMINATED · sponsor: **Navire Pharma Inc., a BridgeBio company** · enrollment: 28 (actual)

## Conditions studied

- Solid Tumor, Adult
- Metastatic Solid Tumor
- Metastatic NSCLC
- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** BBP-398
- **DRUG:** sotorasib

## Key facts

- **NCT ID:** NCT05480865
- **Lead sponsor:** Navire Pharma Inc., a BridgeBio company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-07-06
- **Primary completion:** 2024-08-22
- **Final completion:** 2024-08-22
- **Target enrollment:** 28 (ACTUAL)
- **Why stopped:** Business Reasons
- **Last updated:** 2024-12-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05480865

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05480865, "SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05480865. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*